| |
| |
|
| Insider
Information: |
Foletta Mark G |
| Relationship: |
EVP & Chief Financial ... |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
110,512 |
|
|
Indirect Shares
|
59,092 |
|
|
| Direct
Value |
$1,208,318 |
|
|
|
Indirect Value
|
$7,383,545 |
|
|
| Total
Shares |
169,604 |
|
|
| Total
Value |
$8,591,863 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
1
|
|
Stock
price went up :
|
1
|
1
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
1.0
|
| Percentage
Gain/Loss : |
 8.1%
|
13.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amylin Pharmaceuticals Inc |
AMLN |
SVP, Chief Financial O... |
2012-08-08 |
0 |
2012-08-08 |
0 |
Premium* |
|
|
DexCom Inc |
DXCM |
Director |
2023-05-18 |
3,306 |
2023-05-18 |
59,092 |
Premium* |
|
|
Regulus Therapeutics Inc. |
RGLS |
Director |
2017-12-04 |
81,910 |
2015-08-13 |
0 |
Premium* |
|
|
AMN Healthcare Services Inc |
AHS |
Director |
2024-04-19 |
10,254 |
2016-04-20 |
0 |
Premium* |
|
|
Forte Biosciences Inc |
FBRX |
EVP & Chief Financial ... |
2019-05-28 |
15,042 |
2017-04-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
141 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
• – – |
2008-02-01 |
4 |
A |
$37.00 |
$6,734 |
D/D |
182 |
23,753 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
• – – |
2007-02-28 |
4 |
A |
$33.07 |
$7,673 |
D/D |
232 |
23,242 |
0 |
- |
|
| AHS |
AMN Healthcare Services I... |
Director |
– • – |
2022-11-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
300 |
14,115 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP Chief Financial Officer |
• – – |
2010-02-03 |
4 |
A |
$17.83 |
$7,346 |
D/D |
412 |
26,412 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
• – – |
2007-01-31 |
4 |
A |
$36.07 |
$15,005 |
D/D |
416 |
23,010 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial Officer |
• – – |
2011-12-31 |
5 |
D |
$0.00 |
$0 |
D/D |
(488) |
41,699 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2021-10-01 |
4 |
AS |
$538.02 |
$271,547 |
I/I |
(500) |
13,597 |
0 |
% |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2021-11-01 |
4 |
AS |
$615.13 |
$313,162 |
I/I |
(500) |
13,097 |
0 |
% |
|
| AHS |
AMN Healthcare Services I... |
Director |
– • – |
2024-02-29 |
4 |
B |
$56.90 |
$28,450 |
D/D |
500 |
8,573 |
2.39 |
% |
|
| AMLN |
Amylin Pharmaceuticals In... |
VP Finance & CFO |
• – – |
2006-01-31 |
4 |
A |
$19.46 |
$16,103 |
D/D |
550 |
27,048 |
|
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
Sr VP Finance & CFO |
• – – |
2009-02-03 |
4 |
A |
$11.80 |
$6,903 |
D/D |
585 |
24,839 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial Officer |
• – – |
2010-04-06 |
4 |
OE |
$13.25 |
$8,454 |
D/D |
638 |
28,138 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
VP Finance & CFO |
• – – |
2005-10-05 |
4 |
D |
$35.56 |
$25,034 |
D/D |
(704) |
26,498 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial OfficerSV |
• – – |
2012-07-25 |
4 |
A |
$14.62 |
$12,866 |
D/D |
880 |
73,370 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2020-05-22 |
4 |
A |
$0.00 |
$1 |
D/D |
895 |
895 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2021-05-20 |
4 |
A |
$0.00 |
$0 |
I/I |
895 |
14,097 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2021-05-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(895) |
0 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2018-08-24 |
4 |
S |
$137.50 |
$137,503 |
I/I |
(1,000) |
17,095 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2019-02-15 |
4 |
AS |
$148.52 |
$148,723 |
I/I |
(1,000) |
16,095 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2019-03-15 |
4 |
AS |
$146.92 |
$150,279 |
I/I |
(1,000) |
15,095 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2019-04-15 |
4 |
AS |
$116.96 |
$118,977 |
I/I |
(1,000) |
14,095 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2019-05-15 |
4 |
AS |
$118.65 |
$121,895 |
I/I |
(1,000) |
13,095 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2019-12-03 |
4 |
AS |
$221.34 |
$227,593 |
I/I |
(1,000) |
16,147 |
0 |
- |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2020-01-03 |
4 |
AS |
$217.61 |
$218,053 |
I/I |
(1,000) |
15,147 |
0 |
% |
|
| DXCM |
DexCom Inc |
Director |
– • – |
2020-02-03 |
4 |
AS |
$236.84 |
$237,843 |
I/I |
(1,000) |
14,147 |
0 |
% |
|
141 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
